Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0001193125-26-428018

Chief Financial Officer bought 5,500 shares at $26.10 ($143,550)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Ignelzi Troy A. Chief Financial Officer 2026-10-21 Purchase +5,500 $26.10 $143,550 15,500 D
Open-market purchases · 5,500 sh · avg $26.10 · $143,550
Loading xslF345X06/ownership.xml…